Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.